http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112300082-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fb38ebd40c70e97cc5f1519c6699162 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-59 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056 |
| filingDate | 2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_404e6a64e78e75c6ee59d5caadbabab6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_871f12157d35a9df6113b293d729227d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c7760cfc439a9854cbeb2783a9a0975 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c102749e04af70ec638f382203c328f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bac0c67eefc774154aec9c47517931d8 |
| publicationDate | 2021-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112300082-A |
| titleOfInvention | A kind of phenylpiperazine quinazoline compound or its pharmaceutically acceptable salt, preparation method and use |
| abstract | The invention discloses a phenylpiperazine quinazoline compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof. The phenylpiperazine quinazoline compound or a pharmaceutically acceptable salt thereof has specific structures of the following general formulae (I), (II) and (III). The method for synthesizing these compounds provided by the present invention is easy to realize and has low cost, and can produce anti-tumor effects from the dual targets of EGFR kinase inhibition and integrin αvβ3 receptor inhibition. In vitro and in vivo experimental studies have shown that these compounds have antitumor activity in vitro and in vivo, and the in vivo antitumor activity of compound QJJ‑12 is similar to the clinical drug gefitinib. The compounds can also inhibit the activity of EGFR kinase or EGFR T790M/L858R double mutant kinase, inhibit the horizontal migration ability of HUVEC cells, and can compete with αvβ3 antibody for binding to the integrin αvβ3 receptor on the surface of HUVEC cells. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113956234-A |
| priorityDate | 2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 363.